Product category:
Chemicals and biochemicals
News Release from: Curacyte
Edited by the Laboratorytalk Editorial
Team on 03 July 2003
Taking the shock out of cancer therapy
Curacyte receives FDA clearance for clinical trial of PHP as an adjunct to IL-2 cancer therapy to reduce the effects of shock, which frequently limits the dose of IL-2 that can be given
Curacyte, a Munich-based drug development company focused on novel treatments of inflammatory diseases, thrombotic disorders, and cancer has announced that its US IND for conducting a phase I study with pyridoxalated hemoglobin polyoxyethylene (PHP) as an adjunct to high-dose interleukin-2 (IL-2) therapy in patients suffering from metastatic renal cell carcinoma (RCC) or melanoma has passed FDA review and that all requirements have been established to initiate this study PHP is currently in a phase III pivotal study as a treatment for patients suffering from distributive shock and this phase I trial seeks to establish an additional indication for PHP in an area of unmet medical need
This article was originally published on Laboratorytalk on 6 Dec 2001 at 8.00am (UK)
Related stories
Akcros invests in solid stabilisers
To meet growing demand for PVC stabilisers, Akcros Chemicals will invest in increased production of the Interlite ZP range of solid mixed metal soap stabilisers at its Eccles, UK, facility
MBO for Akcros
Akzo Nobel plastics and processing additives business unit, making lead stabilisers for polymer products sold, to management, and to trade under the new name Allstab
PHP has been shown to be a scavenger of nitric oxide (NO).
NO-related hypotension is a dose-limiting side effect of high-dose IL-2 treatment in metastatic RCC and melanoma.
Shock is a frequent adverse event, and patients can rarely receive their full dose of IL-2 and as a consequence may not optimally benefit from IL-2 therapy.
Further reading
Purpose-built state-of-the-art facilities
New facilities operate to the latest ISO 2000/ PS 9100 standards and include new laboratories where product testing is conducted according to industry and customer specifications
Folic acid kit meets with approval
Food manufacturers worldwide now have a trusted and effective routine means to rapidly meet legal requirements on vitamin fortification
The potential clinical benefit of PHP administration to both patients and physicians may be two-fold: PHP may decrease the incidence of dose-limiting hypotension and shock and could, therefore, improve the outcomes of IL-2 anti-tumour therapy.
The phase I study planned by Curacyte is designed to study the safety, tolerability and activity of continuous infusion of PHP in patients receiving high-dose IL-2 therapy.
The study will be open-label and a total of 20 patients will be randomised to either the control or the treatment arm.
It will be conducted at the Huntsman Cancer Institute, University of Utah, USA.
Joseph DeAngelo, chief development officer of Curacyte, stated: "The initiation of the second clinical trial for our lead product represents an important milestone in our development strategy for PHP.
The outcome of this phase I study may help us establish a line extension of PHP in another area of unmet medical need.
Scientifically, the results of this study may corroborate the clinical utility of PHP as a NO scavenger and pave the way for exploring other areas of shock." PHP is a chemically-modified human hemoglobin and represents Curacyte's most advanced product in development.
PHP is currently in a phase III pivotal study as a treatment for patients suffering from distributive shock affecting more than 1.2 million patients annually.
The therapeutic utility of PHP is based on several physiological functions of hemoglobin, the most important of which is the ability of hemoglobin to bind and metabolise excess and toxic levels of nitric oxide, the main cause of shock.
• Curacyte: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
